Extended Data Table 2 Cohort characteristics for cluster transitions between preapheresis and preinfusion

From: An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

  1. Patients across all cohorts (I - IV) are included in these analyses. Bridging therapy: antineoplastic therapy administered between apheresis and lymphodepleting chemotherapy prior to CAR-T infusion. Vein-to-vein time: the amount elapsed time between T cell collection (apheresis) and CAR-T cell infusion.
  2. I., Inflammatory Cluster; LDH, lactate dehydrogenase; NI., Noninflammatory; IQR, interquartile range.
Back to article page